New Delhi: The Union Ministry of Health and Family Welfare has proposed amendments to the Drugs Rules, 1945, to make it mandatory for pharmaceutical manufacturers to formally designate qualified and experienced personnel responsible for approving the release of every drug batch.
The proposed changes seek to strengthen accountability, improve documentation and establish clear responsibility for batch-release decisions before medicines enter the distribution chain.
The amendments also propose a prescribed format for the Batch Release Certificate and require manufacturers to maintain records of batch-release activities in accordance with specified requirements.
What Are the Proposed Changes to the Drugs Rules, 1945?
Under the proposed framework, applicants seeking drug manufacturing licences under the relevant provisions of the Drugs Rules, 1945, will have to designate a person with appropriate qualifications and experience to oversee batch release.
Read Also: Centre Proposes Stricter Rules for Pharmacies and Wholesalers Advertising Prescription Drugs
The key proposed requirements include:
- Formal authorisation: Manufacturers must formally authorise a suitably qualified and experienced person to undertake batch release.
- Batch-release documentation: Prescribed records must be maintained for every manufactured batch.
- Batch Release Certificate: A standardised format for the certificate will be introduced under the Rules.
- Clear accountability: Responsibility for approving the release of a drug batch will be formally assigned to an authorised individual.
The proposed amendments aim to make batch-release decisions more transparent and traceable within the pharmaceutical manufacturing process.
Why Is Authorisation for Drug Batch Release Important?
Batch release is an important quality-control stage in pharmaceutical manufacturing. Before a manufactured batch is released for distribution, its relevant quality parameters and supporting documentation must be reviewed.
This process helps establish whether the batch meets the applicable quality requirements.
At present, manufacturing licence applications require manufacturers to provide details of competent technical staff responsible for manufacturing and testing. However, the existing provisions do not specifically require them to identify the individual formally authorised to undertake batch release.
The proposed amendments seek to address this gap by introducing an explicit requirement for designated personnel.
How Will the Proposed Rules Strengthen Drug Quality Assurance?
The proposed changes are intended to establish a more structured system of responsibility and documentation in pharmaceutical manufacturing.
The expected regulatory benefits include:
- Greater accountability: A formally authorised individual will be responsible for batch-release decisions.
- Improved traceability: Prescribed records will help track the decisions and documentation associated with each batch.
- Standardised certification: A prescribed Batch Release Certificate format will introduce uniformity in documentation.
- Stronger quality oversight: The requirements will add another layer of review before medicines are released for distribution.
- Better GMP compliance: The framework is expected to support manufacturers in strengthening compliance with applicable Good Manufacturing Practices (GMP).
The changes are intended to reinforce the existing quality-assurance framework rather than replace other manufacturing and testing requirements.
Manufacturers and Stakeholders Can Submit Objections and Suggestions
The Health Ministry has invited objections and suggestions from stakeholders on the proposed amendments.
Submissions may be sent to the Ministry of Health and Family Welfare at its official postal address or through its official email address ([email protected]).
The proposals will be considered through the prescribed regulatory process before any final notification is issued.
Proposed Amendment to Strengthen Pharmaceutical Manufacturing Oversight
The proposed changes to the Drugs Rules, 1945, form part of efforts to strengthen quality assurance and accountability in India’s pharmaceutical manufacturing sector.
By requiring manufacturers to formally authorise qualified personnel for batch release and maintain standardised records, the Health Ministry aims to improve oversight of the process through which medicines are cleared for distribution.
The amendments are currently at the proposal stage. Their final provisions will depend on the outcome of the consultation process and subsequent government notification.
